Login to Your Account

Wrong ‘mirve’? Forward 1 transformed into phase III trial as Immunogen chalks loss

By Randy Osborne
Staff Writer

Friday, April 29, 2016

About the 5 percent drop in overall response rate in the expanded phase I trial with the company’s ADC for ovarian cancer, Immunogen Inc.’s chief development officer, Charles Morris, said he was “not sure I’d call it significant.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription